The Novavax COVID-19 vaccine.
UK trials have indicated that the Novavax COVID-19 vaccine is 89.3% effective at preventing Covid-19, and around 86% effective at protecting against the UK variant. bbc.com/news/uk-55850352
The European Commission, which coordinates talks and orders with vaccine makers, had planned to sign a deal early this year, 2021, for at least 100 million doses of Novavax’s vaccine, with an option for another 100 million.
Unfortunately for the European Union countries, this has not yet eventuated.
The UK, not being constrained by EU rules, has already secured 60 million doses, which will be made in Stockton-on-Tees in north-east England.
Australia, also not constrained by EU rules, finalised an agreement in January 2021, for 51 million doses of the Novavax vaccine. novavax.com/…/novavax-finalizes-agreement-commonwealth-australia-51-million
Novavax can be stored at regular fridge temperature. This allows easier distribution than others that require very high freezer temperatures.
Novavax has eight manufacturing locations, including the Serum Institute of India, the world’s biggest vaccine maker.
Serum has recently suspended major exports of Novavax, due to the US temporarily banning exports of critical raw materials needed for their production.